Efficacy of two insertions of 100-minute releasing quinacrine hydrochloride pellets for non-surgical female sterilization.
Extensive research has been undertaken to develop a simple method of non-surgical female sterilization. Zipper and associates identified quinacrine hydrochloride as a drug likely to produce tubal occlusion when placed into the uterus. Zipper's early work with a solution of quinacrine led to the development of quinacrine pellets, a delivery system that was designed to bring the quinacrine into prolonged contact with the tubal ostia through extended uterine retention. Three transcervical uterine insertions of 10-minute releasing quinacrine hydrochloride pellets performed at monthly intervals have produced a 12-month pregnancy rate of 3.3 per 100 women. The ultimate goal is to develop an effective, single insertion procedure, but the performance of the quinacrine pellets in occluding tubes has necessitated more than one insertion. FHI developed a 100-minute extended release pellet system with the expectation that more prolonged drug exposure would produce a higher rate of tubal closure. A study of the 100-minute releasing pellet system has been conducted in Santiago, Chile. Two monthly insertions in 112 women has resulted in a 12-month pregnancy rate of 2.0 per 100 women. Postprocedure problems occurring within the first year were reported by 13% of the women; most were minor and transitory.
Zipper
J
J
Hospital Sotero del Rio, University of Chile, Santiago.
Cole
L P
LP
Rivera
M
M
Brown
E
E
Wheeler
R G
RG
D000328:Adult; D004343:Drug Implants; D005260:Female; D006801:Humans; D011247:Pregnancy; D011796:Quinacrine / Q000008:administration & dosage*; D013246:Sterilization, Tubal / Q000379:methods*; D014599:Uterus
D004343:Drug Implants; D011796:Quinacrine